Abstract
The aim of the study was to compare the distribution of therapeutic efficacy and sexual dysfunction during maintenance paroxetine treatment in 17 males and 38 females genotyped and phenotyped to determine their CYP2D6 metabolic status. Clinical results were monitored on scales Clinical Global Impression-Severity of Illness Scale (CGIS) and Arizona Sexual Experience Scale (ASEX). The phenotype procedure showed 7 males and 12 females with extensive metabolic status (EM) and 10 males and 26 females with poor metabolic status (PM). No variation in therapeutic efficacy between male and female subjects classified as PM and those marked as EM was found. A significantly higher rate of sexual dysfunction (p = 0.01) was recorded among females with a PM phenotype.
Publication types
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents, Second-Generation / administration & dosage
-
Antidepressive Agents, Second-Generation / adverse effects*
-
Cytochrome P-450 CYP2D6 / genetics*
-
Cytochrome P-450 CYP2D6 / metabolism
-
Czech Republic
-
Depression / drug therapy*
-
Depression / genetics*
-
Depression / metabolism
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Libido / drug effects
-
Male
-
Middle Aged
-
Paroxetine / administration & dosage
-
Paroxetine / adverse effects*
-
Phenotype
-
Sexual Dysfunctions, Psychological / chemically induced*
-
Sexual Dysfunctions, Psychological / metabolism
-
Treatment Outcome
Substances
-
Antidepressive Agents, Second-Generation
-
Paroxetine
-
Cytochrome P-450 CYP2D6